ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ÉúÃü¿ÆÑ§Ñ§Ôº²ÜÓÀ³¤½ÌÊÚÑо¿ÍŶÓÔÚH7N9Á÷¸Ð²¡¶¾¹ãÆ×ÒßÃçÑо¿ÁìÓòÈ¡µÃÍ»ÆÆÐÔÏ£Íû

ÔĶÁÁ¿£º

¿ËÈÕ£¬£¬£¬ÉúÃü¿ÆÑ§Ñ§ÔºÓк¦ÉúÎï¿ØÖÆÓë×ÊԴʹÓùú¼ÒÖØµãʵÑéÊÒ²ÜÓÀ³¤½ÌÊÚÍŶÓÔÚ¹ú¼Ê¿¹²¡¶¾È¨ÍþÆÚ¿¯¡¶Antiviral Research¡·ÉϽÒÏþÁËÎÊÌâΪ¡°A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬±¨µÀÁËÒ»ÖÖ¶ÔѪÄýËØÂÑ°× £¨Hemagglutinin£¬£¬£¬HA£©¾ÙÐнṹÉè¼ÆµÄH7N9Á÷¸Ð²¡¶¾È«²¡¶¾Ãð»îÒßÃ磬£¬£¬²¢ÇÒ֤ʵÕâÖÖÈ«²¡¶¾Ãð»îÒßÃç¿ÉÒԴ̼¤»úÌ屬·¢H7N9ÑÇÐÍÄÚ¹ãÆ×½»Ö¯ÃâÒß·´Ó³ºÍ½»Ö¯±£»£»£»¤¡£¡£²ÜÓÀ³¤½ÌÊÚΪ±¾ÎÄͨѶ×÷Õߣ¬£¬£¬²©Ê¿Ñо¿ÉúÍõÑóΪ±¾ÎĵÚÒ»×÷Õß¡£¡£

×Ô2013Äê3ÔÂÎÒ¹úÊ״ᨵÀH7N9Á÷¸Ð²¡¶¾Ñ¬È¾ÈËÒÔÀ´£¬£¬£¬H7N9Á÷¸Ð²¡¶¾ÒѾ­ÂÄÀúÁË5²¨Ê¢ÐУ¬£¬£¬Ñ¬È¾²¡Àý1364Àý£¨×èÖ¹2017Äê4ÔÂ1ÈÕ£©£¬£¬£¬éæÃüÂÊ´ï30%¡£¡£H7N9Á÷¸Ð²¡¶¾²»µ«¾ßÓÐDZÔÚ´óÊ¢ÐеÄÍþв£¬£¬£¬Ò²¶ÔÑøÇÝÒµÔì³ÉÁËÖØ´óµÄËðʧ¡£¡£¸úÆäËûÁ÷¸Ð²¡¶¾Ò»Ñù£¬£¬£¬H7N9Á÷¸Ð²¡¶¾±äÒìÊ®·ÖѸËÙ£¬£¬£¬ÒѾ­ÐγÉÁ˶à¸ö»ùÒòÐÍ£¬£¬£¬Òò´ËÑÐÖÆ¾ßÓйãÆ×½»Ö¯±£»£»£»¤Ð§¹ûµÄH7N9Á÷¸Ð²¡¶¾ÒßÃçÊ®·ÖÐëÒª¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ÖØ×éH7N9Á÷¸Ð²¡¶¾µÄÕü¾È

²ÜÓÀ³¤½ÌÊÚÍŶÓ֮ǰµÄÑо¿Ö¤ÊµH3ÑÇÐÍHAÂѰ׿çÄ¤Çø£¨Transmembrane domain£¬£¬£¬TM£©ÓëHAÂѰ×ÎȹÌÐÔ¡¢¡¢¡¢HAÂѰ׽»Ö¯ÃâÒßÔ­ÐÔ¹ØÏµÇ×½ü£¬£¬£¬Í¨¹ýHA¿çÄ¤ÇøÖû»Õ½ÂÔ¿ÉÒÔÌá¸ßÈý¾Û»¯H1¡¢¡¢¡¢H5ºÍH9ÑÇÐÍHAÂѰ׵ÄÑÇÐͼ佻֯±£»£»£»¤Á¦¡£¡£ÔÚH7N9¹ãÆ×ÒßÃçµÄÑо¿ÖУ¬£¬£¬¸ÃÍŶӽ«H7N9Á÷¸Ð²¡¶¾HAÂѰ×TMÖû»ÎªH3ÑÇÐÍHA TM£¬£¬£¬²¢Í¨¹ý·´ÏòÒÅ´«ÊÖÒÕÕü¾È³ö°üÀ¨TMÖû»µÄÖØ×éH7N9Á÷¸Ð²¡¶¾¡£¡£ÔÚСÊó¶¯ÎïÄ£×ÓÖУ¬£¬£¬ÖØ×鲡¶¾ÖƱ¸µÄÈ«²¡¶¾Ãð»îÒßÃçÄܹ»ÓÕµ¼»úÌ屬·¢Õë¶Ô²î±ð·ÖÖ§¶¾Ö꿹ԭµÄ¸ü¸ßµÄHI¿¹Ìå¡¢¡¢¡¢HAÌØÒìÐÔIgG¿¹Ìå¡¢¡¢¡¢HAÌØÒìÐÔIFN-¦Ãϸ°ûÒò×Ó¡£¡£¸ÃÒßÃçÄܹ»¶ÔСÊóͬԴ»òÒìÔ´H7N9²¡¶¾¹¥¶¾ÌṩÍêÈ«±£»£»£»¤£¬£¬£¬¾­ÓÉÃâÒßµÄСÊóÔÚ¹¥¶¾ºó¼ì²â²»µ½·Î²¡¶¾µÎ¶È¡¢¡¢¡¢ÎÞÏÔ×ŷβ¿²¡±äºÍÑ×Ö¢·´Ó³¡£¡£

²ÜÓÀ³¤½ÌÊÚÍŶӺã¾Ã¾ÙÐж¯Îﲡ¶¾Ñ§Ñо¿£¬£¬£¬ÏȺó»ñµÃ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢¡¢¡¢863ÏîÄ¿¡¢¡¢¡¢¹ú¼ÒÖØµãÑз¢ÍýÏëÏîÄ¿¡¢¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ðµÈ¿ÆÑÐÏîÄ¿µÄ×ÊÖú£¬£¬£¬½ÒÏþSCIÂÛÎÄ30ÓàÆª¡£¡£ÏÖÔÚ¸ÃÍŶÓÖÂÁ¦ÓÚÁ÷¸Ð²¡¶¾·À¿Ø¡¢¡¢¡¢¹Ú×´²¡¶¾£¨ÖíÊ¢ÐÐÐÔ¸¹Ðº²¡¶¾PEDV¡¢¡¢¡¢¼¦Ñ¬È¾ÐÔÖ§Æø¹ÜÑײ¡¶¾IBV£©ÒÅ´«ÑÝ»¯ºÍÃâÒßÌÓÒÝ»úÖÆÑо¿£¬£¬£¬ÒÑ»ñµÃ¶àÏîÑо¿Ð§¹û¡£¡£

¡¾ÍøÕ¾µØÍ¼¡¿